Riskpilot← Back to searchSign inGet full accessPharmista Technologies AB
ABActiveOrg 5592476500Stadsgården 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201-4 employees
Revenue 2024
SEK 2,4M
+1341% vs 2023
EBITDA margin
-3.1%
-324% vs 2023
Equity ratio
13.3%
Financial strength
Net profit 2024
SEK -51K
| Revenue | SEK 2,4M | +1341% |
| EBITDA | SEK -74K | -324% |
| Net profit | SEK -51K | — |
| Total assets | SEK 1,6M | +67% |
| Equity | SEK 214K | -19% |
| Employees | — | — |
Legal name
Pharmista Technologies AB
Org number
5592476500
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 mars 2020
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Utveckling, tillverkning och försäljning av återanvändbara graviditetstest och andra medicintekniska produkter.
Address
Stadsgården 6
Email
alice@pharmista.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 13 | 116 | 166 | 2 392 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | −11 | −29 | 33 | −74 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −11 | −29 | 33 | −74 |
| Net financials | −2 | −14 | −11 | −34 | 23 |
| Profit before tax | −1 | −18 | −40 | 0 | −51 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 | −18 | −40 | 0 | −51 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 24 | 374 | 643 | 961 | 1 609 |
| Equity | 24 | 306 | 265 | 265 | 214 |
| Long-term debt | 0 | 56 | 308 | 658 | 949 |
| Short-term debt | 0 | 12 | 69 | 38 | 446 |
| Total debt | — | 68 | 377 | 696 | 1 395 |
EBITDA margin
-3.1%
This company
15.8%
Market median
-120% vs market
20202024
Equity ratio
13.3%
This company
38.2%
Market median
-65% vs market
20202024
Return on equity
-23.8%
This company
18.4%
Market median
-229% vs market
20202024
Net profit margin
-2.1%
This company
8.1%
Market median
-126% vs market
20202024
Asset turnover
1.49×
This company
1.12×
Market median
+33% vs market
20202024
Debt / equity
6.52×
This company
0.62×
Market median
-952% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-03-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AA Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
MS Audit | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmista Technologies AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alice Anna Lovisa Mattsson | Chief Executive Officer | 0 companies |
| Maria Sofia Ekelund | Audit | 0 companies |
| Börje Karl-Egron Sellergren | Deputy Board Member | 0 companies |
| Annette Cecilia Elise Säfholm | Chairman | 0 companies |
| Robert Porter | Board of Directors | 0 companies |
| Erik Henau | Board of Directors | 0 companies |